Alphatec Holdings CFO John Koning buys $99,146 in common stock By Investing.com
Alphatec Holdings CFO John Koning purchased 14,601.7699 shares of the company's common stock for approximately $99,146 on November 16, 2026. This transaction occurred while the stock was trading near its 52-week low. The company recently reported Q3 2026 earnings that missed analyst expectations, leading TD Cowen and Needham to lower their price targets while maintaining a Buy rating.
Form 4 Alphatec Holdings Inc: John Todd Koning (CFO) For: 16 November By Investing.com
This article reports on a Form 4 filing for Alphatec Holdings Inc, specifically detailing an action by CFO John Todd Koning for November 16. It indicates that the company's stock, ATEC, saw a 2.36% increase. The content is brief, primarily serving as an announcement for the SEC filing.
Lawsuit probes Alphatec over missed earnings and revenue guidance cuts causing stock plunge
Pomerantz LLP is investigating Alphatec Holdings for potential securities fraud after the company missed third-quarter revenue estimates and lowered its full-year 2026 guidance, leading to a significant stock price drop. The investigation will examine whether Alphatec engaged in unlawful business practices that negatively impacted investor confidence and stock value. This news comes as the health sector experiences widespread declines, with 117 out of 150 US health-sector stocks tradable on Pluang falling today.
Alphatec Holdings (ATEC) CFO Koning bought 14,601.77 shares for $99.1K at $6.79
Alphatec Holdings (ATEC) CFO John Todd Koning purchased 14,601.77 shares for approximately $99.1K at a price of $6.79 per share on November 16, 2026. This transaction increased his direct holdings to 615,322.77 shares. The article also provides historical context on ATEC's stock performance following previous headlines and details other recent insider transactions.
Alphatec Holdings stock hits 52-week low at 6.8 USD By Investing.com
Alphatec Holdings stock has plummeted to a 52-week low of $6.80 USD, reflecting a 65.55% decrease over the past year from its high of $23.29. Despite this downturn, InvestingPro data suggests the stock is undervalued, and analysts anticipate profitability for the company this year, noting its 15% revenue growth and strong 71% gross profit margin. The decline follows a Q3 2026 earnings miss, leading analysts to revise down their price targets, although maintaining "Buy" ratings.
Alphatec Holdings, Inc. Stock 12‑Month Price Target Cut to $12.46, Implies 77% Upside
Alphatec Holdings, Inc.'s average 12-month price target has been reduced from $13.29 to $12.46 by 13 analysts, with individual forecasts ranging from $8 to $17 per share. Despite the cut, the updated target suggests a substantial 77% potential upside from the November 12 closing price. The consensus rating for ATEC remains a "Buy," with 11 analysts recommending Buy and 2 recommending Hold.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alphatec Holdings, Inc. - ATEC
Pomerantz LLP is investigating potential securities fraud claims against Alphatec Holdings, Inc. (NASDAQ: ATEC) after the company reported third-quarter 2026 financial results that missed consensus estimates and revised down its full-year guidance. This news led to a significant 38.08% drop in Alphatec's stock price on October 30, 2026, prompting the law firm to advise affected investors to contact them regarding potential class action involvement.
87 new hires receive stock-linked awards from Alphatec, totaling 243,089 units.
Alphatec Holdings, Inc. announced its participation in two upcoming investor conferences in December 2026, where management will engage with investors through one-on-one meetings and a fireside chat. Concurrently, the company granted inducement awards of 243,089 restricted stock units to 87 new non-executive employees, vesting over four years. These awards are intended to incentivize new talent in accordance with Nasdaq listing rules.
Alphatec Holdings, Inc. (NASDAQ: ATEC) INVESTIGATION ALERT:
The Portnoy Law Firm has announced an investigation into Alphatec Holdings, Inc. (NASDAQ: ATEC) concerning potential securities fraud. This investigation follows Alphatec's third-quarter 2026 financial results, which reported revenue falling short of projections and a downward revision of full-year 2026 guidance, leading to a significant 38.08% drop in the company's stock price on October 30, 2026. The firm is examining whether Alphatec made false or misleading public statements regarding its financial performance and product adoption.
Alphatec Holdings (ATEC) director Valentine bought 35,000 shares for $243K at $6.93
Alphatec Holdings (ATEC) director Keith Valentine purchased 35,000 shares of the company's common stock for $243,000 at a weighted average price of $6.93 per share on November 10, 2026. This transaction increased his direct holdings by 13% to a total of 299,283 shares. The filing notes that the shares were bought in multiple transactions ranging from $6.92 to $6.94.
Alphatec Holdings (ATEC) director Valentine bought 35,000 shares for $243K at $6.93
Alphatec Holdings (ATEC) director Keith Valentine recently purchased 35,000 shares of the company's common stock for a total of $242,550 at a weighted average price of $6.93 per share. This transaction, reported on November 10, 2026, increased his direct holdings by 13% to 299,283 shares. The article also provides historical context on ATEC's stock performance after previous headlines and details other insider transactions.
Form 4 Alphatec Holdings Inc: Keith Valentine (Director) For: 10 November
This article reports on a Form 4 filing for Alphatec Holdings Inc., indicating an insider transaction by director Keith Valentine on November 10. The filing, published on Investing.com, notes the transaction without providing further details on the nature or value of the transaction.
Form 4 Alphatec Holdings, Inc. For: Nov 10 Filed by: Valentine Keith
This article reports a Form 4 filing for Alphatec Holdings, Inc. (ATEC) by Keith Valentine, a director. The filing details the acquisition of 35,000 shares of common stock at a weighted average price of $6.93 per share on November 10, 2026, bringing his total beneficial ownership to 299,283 shares. The transaction was a purchase (P) and is reported directly.
Alphatec Holdings (ATEC) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky is investigating Alphatec Holdings (ATEC) for potential securities law violations after the company missed Wall Street's third-quarter 2026 adjusted EPS and revenue consensus estimates. ATEC shares dropped significantly following the late-October earnings report, which also included slashed full-year guidance. Investors who suffered losses are encouraged to contact Levi & Korsinsky for a free review of their potential recovery.
Levi & Korsinsky Notifies Investors of Pending Investigation into Securities Claims Involving Alphatec Holdings (ATEC)
Levi & Korsinsky is investigating Alphatec Holdings (NASDAQ: ATEC) for potential violations of federal securities laws after the company cut its full-year 2026 revenue outlook due to a temporary international supply constraint. This reduction came less than three months after the CEO stated that its "clinical distinction model translates globally" without mentioning any pending constraints. The investigation focuses on whether Alphatec adequately disclosed this international supply constraint to investors prior to the revised outlook, which caused a sharp decline in ATEC's stock price.
ATEC Investors Have Opportunity to Join Alphatec Holdings, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Alphatec Holdings, Inc. (NASDAQ: ATEC) following a significant drop in share prices. This investigation comes after Alphatec lowered its full-year revenue guidance when reporting its Q3 2026 financial results. SBS is encouraging Alphatec shareholders who have suffered losses to participate in the fraud investigation.
Alphatec Holdings, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ATEC) 2026-11-03
Alphatec Holdings, Inc. published its slide deck in conjunction with its 2026 Q3 earnings call. The company reported EPS of $0.09, missing estimates by $0.00, and revenue of $221.17M, missing by $3.97M, though representing a 12.55% year-over-year increase.
Director Demski David M bought $408,600 worth of shares (60,000...
Director David M. Demski purchased 60,000 shares of Alphatec Holdings Inc. (NASDAQ: ATEC) for $408,600, increasing his direct ownership by 14% to a total of 491,635 units. This insider transaction was reported via an SEC Form 4 filing and was promptly disseminated by Quantisnow.
ATEC SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Alphatec Holdings
SueWallSt.com has initiated an investigation into Alphatec Holdings (NASDAQ: ATEC) after the company cut its full-year 2026 revenue guidance to approximately $862 million, attributing the reduction to lower biologics attachment rates, softer thoracolumbar procedure volumes, and temporary international supply constraints. This marks the second time Alphatec has lowered its projection this year, leading to potential securities law violations. Investors who suffered losses on ATEC shares are encouraged to contact SueWallSt.com for a confidential review of their claims.
Wells Fargo maintains Alphatec Holdings at Overweight, lowers price target to $12 from $14
Wells Fargo has reaffirmed its "Overweight" rating for Alphatec Holdings (ATEC) but has reduced its price target from $14 to $12, marking a 14.3% decrease. This new price target suggests a modest 5.5% upside from the stock's closing price of $11.37 on October 29. Investors can find more detailed price target data and analyst recommendations for Alphatec Holdings on TradingView's platform.
Alphatec Plunges 37%. A Bone-Graft Slump Hits the Spine Specialist’s Stock.
Alphatec stock experienced its worst day in over a decade, plummeting 37% after the company missed its third-quarter estimates and significantly lowered its full-year guidance. The spine specialist's stock has fallen 46% this year, largely due to a slump in bone-graft sales. This downturn reflects challenges in the company's financial performance and market outlook.
Alphatec Holdings Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Alphatec Holdings (ATEC)
Levi & Korsinsky is investigating Alphatec Holdings (NASDAQ: ATEC) after the company cut its 2026 revenue guidance by approximately $20 million, less than three months after reaffirming an $882 million outlook. The revised forecast of approximately $862 million, down from an initial $890 million, led to a drop in ATEC shares. Shareholders who suffered losses are encouraged to have their ATEC losses evaluated as part of the ongoing investigation into potential securities law violations.
Alphatec Holdings, Inc. Stock 12‑Month Price Target Cut to $14.25, Implies 25% Upside
Alphatec Holdings, Inc.'s average 12-month price target has been reduced by analysts from $15.79 to $14.25, with forecasts ranging from $8 to $24 per share. This updated target suggests a potential upside of approximately 25% from the Oct. 29 closing price. Despite the target cut, the consensus rating from 14 analysts remains a "Buy," with 13 Buys and 1 Hold.
Alphatec Holdings, Inc. Stock 12‑Month Price Target Cut to $14.25, Implies 25% Upside
Alphatec Holdings, Inc.'s average 12-month price target has been reduced from $15.79 to $14.25 by 14 analysts, implying a 25% potential upside from its Oct. 29 closing price. Despite the cut, the consensus rating for ATEC remains "Buy," with 13 analysts recommending a buy and one recommending a hold.
What Alphatec Holdings (ATEC)'s Lowered Outlook Means For Shareholders
Alphatec Holdings reported a net loss of US$5.47 million for Q3 2026 and lowered its full-year revenue guidance to US$862 million due to weaker biologics attachment, softer thoracolumbar procedure volumes, and a packaging defect. Despite these challenges, the company showed improved gross margin, adjusted EBITDA, and free cash flow. The investment narrative now focuses on the company's ability to convert rising case volumes and surgeon adoption into profitability while offsetting biologics pressure.
Case volumes rose about 20%, but revenue missed expectations at Alphatec (ATEC).
Alphatec Holdings, Inc. (ATEC) reported a 13% year-over-year revenue increase to $221.172 million for Q3 2026, with surgical revenue up 14% and case volumes growing approximately 20%. Despite this growth, revenue fell short of expectations primarily due to lower biologics attachment. The company adjusted its full-year 2026 outlook, now expecting approximately $862 million in total revenue and $137 million in adjusted EBITDA.
Alphatec Holdings (ATEC) Offers Market Share Gains and Margin Expansion Potential, Madison Small Cap Fund Says
Madison Small Cap Fund initiated a position in Alphatec Holdings, Inc. (ATEC), a strong competitor in spinal surgery, citing its innovative PTP surgical technique which lowers complication rates and speeds recovery. The fund believes ATEC is well-positioned for continued market share gains due to its innovative products and anticipates margin expansion as revenue scales, especially as larger competitors are seen as "share donors." Despite a challenging Q3 2026 for quality-focused investors, Madison Small Cap Fund outperformed benchmarks, focusing on high-quality companies with strong fundamentals.
Behavioral Patterns of ATEC and Institutional Flows
This article provides an analysis of Alphatec Holdings Inc. (NASDAQ: ATEC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies compelling upside potential due to the absence of resistance levels above the current price. The article also outlines three AI-generated institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, complete with entry zones, targets, and stop losses for different risk profiles.
Alphatec Holdings, Inc. Estimates – NASDAQ:ATEC
This page on TradingView provides financial actuals and analyst estimates for Alphatec Holdings, Inc. (NASDAQ:ATEC). Users can explore reported financial data and compare it with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics, along with visualizing trends over time. The platform also offers disclaimers regarding investment advice.
Alphatec Holdings, Inc. Estimates – SWB:L1Z1
This article provides an overview of Alphatec Holdings, Inc. (SWB:L1Z1) on the Stuttgart Stock Exchange, focusing on its financial estimates. It allows users to explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The content explicitly states that it is not investment advice and encourages users to conduct their own research.
Alphatec Holdings sets October 29 for Q3FY26 results release
Alphatec Holdings, Inc. is scheduled to report its third-quarter 2026 financial results on October 29, 2026, after the market closes. The company will host a live webcast at 1:30 pm PT / 4:30 pm ET on the same day, with a replay available for 12 months on its Investor Relations website. Analysts planning to participate in the Q&A session must register in advance to receive access details.
Press Release: ATEC to Report Third Quarter 2026 Financial Results on October 29, 2026
ATEC Spine, Inc. will report its third quarter 2026 financial results after the market closes on Thursday, October 29, 2026. The company will also host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Individuals can access the webcast live or an archived version later, and dial-in information for the conference call is provided.
ATEC to Report Third Quarter 2026 Financial Results on October 29, 2026
Alphatec Holdings, Inc. (ATEC) announced it will report its third-quarter 2026 financial results on October 29, 2026, after the market close. The company will host a live webcast and question-and-answer session for analysts at 1:30 p.m. PT / 4:30 p.m. ET on the same day. A replay of the webcast will be available for 12 months on ATEC’s Investor Relations website.
Alphatec Holdings (ATEC) Stock Could Be 48% Undervalued As Cash Flow Recovers
Alphatec Holdings (ATEC) shares have dropped significantly this year, prompting an analysis of its valuation based on future cash flow. A Discounted Cash Flow (DCF) model suggests the stock is substantially undervalued, with an intrinsic value much higher than its current trading price of $10.46, assuming a recovery from its current negative free cash flow. This assessment highlights the importance of the company's ability to convert spinal surgery procedure volumes into positive and growing free cash flow.
How Alphatec Holdings Inc. (ATEC) Affects Rotational Strategy Timing
This article provides an analysis of Alphatec Holdings Inc. (ATEC) focusing on its impact on rotational strategy timing, with insights for institutional trading strategies. It presents key findings on sentiment, support and resistance levels, and offers specific position trading, momentum breakout, and risk hedging strategies based on AI models. The analysis also includes a multi-timeframe signal analysis indicating strong near-term and mid-term signals, but a weak long-term outlook for ATEC.
Alphatec Holdings Inc (ATEC) Shares Surge 5.4% -- What GF Score of 74 Tells Investors
Alphatec Holdings Inc (ATEC) shares recently surged by 5.4% but its GF Score of 74, while above average, reveals a mixed financial picture. The stock is considered "Modestly Undervalued" by GF Value, yet faces significant concerns due to low profitability, financial instability, and substantial insider selling. Investors are advised to exercise caution and balance potential upside with inherent risks.
Analysts Are Bullish on These Healthcare Stocks: Zura Bio (ZURA), Alphatec Holdings (ATEC)
Analysts have issued bullish ratings for several healthcare stocks, including Zura Bio (ZURA) and Alphatec Holdings (ATEC). Piper Sandler maintained a Buy rating on Zura Bio with a $26.00 price target, while Stifel Nicolaus also maintained a Buy rating on Alphatec Holdings with a $10.54 price target. Wedbush also maintained a Buy rating on Rocket Pharmaceuticals (RCKT) with a $15.00 price target.
Analysts Are Bullish on These Healthcare Stocks: Zura Bio (ZURA), Alphatec Holdings (ATEC)
The article highlights bullish sentiments from analysts on several healthcare stocks, including Zura Bio (ZURA), Alphatec Holdings (ATEC), and Rocket Pharmaceuticals (RCKT). Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Zura Bio with a $26.00 price target, while Thomas Stephan from Stifel Nicolaus issued a Buy rating on Alphatec Holdings with a $10.54 price target. Yun Zhong from Wedbush also maintained a Buy rating on Rocket Pharmaceuticals with a $15.00 price target, despite a lower average return for the analyst.
Trading the Move, Not the Narrative: (ATEC) Edition
Alphatec Holdings Inc. (NASDAQ: ATEC) is showing divergent sentiment across time horizons, suggesting choppy conditions. Stock Traders Daily's AI models have generated three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. While near-term sentiment is strong, broader alignment is weak, and no clear price positioning signal has been identified.
Form 4 Alphatec Holdings Inc For: 5 October By Investing.com
The article reports on a Form 4 filing for Alphatec Holdings Inc. on October 5th. It mentions that Alphatec Holdings Inc. (ATEC) experienced a -2.75% change. The content primarily focuses on financial market data and related news.
Form 4 Alphatec Holdings Inc For: 5 October
This article from Investing.com reports on a Form 4 filing for Alphatec Holdings Inc. The filing date mentioned is October 5th. The article is very brief and primarily serves as a notification of the filing.
Form 4 Alphatec Holdings Inc For: 5 October By Investing.com
This article reports on the filing of Form 4 by Alphatec Holdings Inc. for transactions that occurred on October 5th. The filing is a standard regulatory disclosure related to insider trading, indicating changes in company ownership or securities by company officers or directors.
ATEC6342884 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Alphatec Holdings, Inc. bond ATEC6342884, with a 0.75% coupon rate maturing on March 15, 2030. It covers key facts about the issuer, bond classification, credit risk assessment, interest payment details, and a coupon payout schedule. The bond has an outstanding amount of 405.00 million USD and is a corporate bond issued by Alphatec Holdings, Inc., a company focused on spinal fusion technology.
ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy
Alphatec Holdings, Inc. (ATEC) has appointed Thomas “Tommy” Carls as Executive Vice President, Data Intelligence and Strategy. In this new role, Carls will lead ATEC's efforts across its EOSedge, EOS Insight, data acquisition and analytics, and the broader InformatiX strategy, aiming to integrate its procedural ecosystem and apply data and predictive analytics to enhance spine surgery. This appointment highlights ATEC's commitment to leveraging data for improved surgical outcomes and personalized patient care, building on Carls' three decades of experience in medical technology and spine.
2,520 shares of Alphatec Holdings (ATEC) are held directly by executive Carls Thomas Andrew.
Alphatec Holdings, Inc. executive Carls Thomas Andrew, EVP, Data & Imaging Solutions, reported direct ownership of 2,520 shares of common stock as of September 14, 2026. This information was filed with the SEC on September 24, 2026, as a Form 3, initial statement of beneficial ownership. The filing indicates a moderate impact and neutral sentiment.
Alphatec names Thomas Carls to lead data intelligence unit
Alphatec Holdings, Inc. has appointed Thomas Carls as Executive Vice President, Data Intelligence and Strategy. Carls, with over 30 years of experience in spine and medical technology, will be responsible for developing and marketing the company's data-driven products and strategies, including EOSedge and InformatiX. This strategic hire aims to enhance Alphatec's procedural ecosystem in spine surgery.
Alphatec Holdings, Inc. Announces Appointment of Thomas "Tommy" Carls as Executive Vice President, Data Intelligence and Strategy
Alphatec Holdings, Inc. has appointed Thomas "Tommy" Carls as Executive Vice President, Data Intelligence and Strategy. In this new role, Carls will lead the company's efforts in data acquisition, analytics, and the broader InformatiX strategy, reporting directly to the CEO. His focus will be on integrating data and predictive analytics across ATEC's procedural ecosystem to enhance surgical insights and improve spine care.
Alphatec (ATEC) Moves 19.7% Higher: Will This Strength Last?
Alphatec (ATEC) shares jumped 19.7% following strong Q2 2026 performance, with earnings of 7 cents per share and revenues of $213.5 million. The company maintains its full-year 2026 revenue guidance of approximately $882 million due to solid case volume growth and surgeon adoption. Despite the recent surge, the stock, currently holding a Zacks Rank #3 (Hold), faces uncertainty as its consensus EPS estimate for the upcoming quarter has remained unchanged, suggesting that continued strength might depend on future earnings estimate revisions.
What Is Driving Attention Around Alphatec Holdings (ATEC)?
Alphatec Holdings (ATEC) recently saw increased market attention due to a firm advance in its stock, renewing focus on its spine-surgery technology business. The company's market activity was directly linked to its healthcare profile, separating its performance from the broader market rebound. This interest was further supported by easing energy concerns and inflation updates that met expectations in the wider US equities market.
Alphatec Holdings CEO Patrick Miles buys $1.01m in common stock
Alphatec Holdings CEO Patrick Miles recently purchased 115,000 shares of the company's common stock for approximately $1.01 million, with the stock currently trading near its 52-week low and identified as undervalued by InvestingPro. This insider purchase follows a 15% increase in Alphatec's second-quarter revenue and an optimistic adjusted EBITDA, although the company was not profitable over the last year. Analysts predict profitability this year, and the company has raised its full-year earnings outlook.